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eA Reassessment of Needs and Practice Patterns in Pharmacologic
Prophylaxis of Venous Thromboembolism Following Elective Major
Surgery
Quadan M, Polk HC Jr, Hohmann SF, et al. Ann Surg 2011;253:215-20.
Conclusion: Physician judgment should be used in determining sus-
ceptibility to venous thromboembolism (VTE) and the need for VTE
prophylaxis in patients undergoing major elective abdominal surgery.
Summary: There were an estimated 900,000 VTE events in U.S.
hospitalized patients in 2005 (Heit JA, et al. American Society of Hematol-
ogy Annual Meeting Abstract 2005;106 abstract 910). However, pulmo-
nary embolism (PE) after elective abdominal surgery seems very uncommon.
Opponents of a “one size fits all” approach to VTE prophylaxis argue
routine VTE prophylaxis for all patients increases cost and compromises
resources to administer what is potentially a dangerous treatment for an
infrequent event in certain categories of patients. They further argue that
trials of VTE prophylaxis use some VTE events as end points for efficacy,
such as calf vein thrombosis, that may not be clinically significant, at least in
the short-term. In 2004 the Kentucky Surgical Care Improvement Project
found a very low rate of PE in 5285 elective specialty surgery patients. There
were 15 PEs detected in these patients, and none were fatal despite erratic
and very limited use of VTE prophylaxis. The authors also queried the
University Health System Consortium database from 2004 and also found a
very low rate of VTE complication in patients undergoing elective opera-
tions (Surg 2008;144:654-660). It is possible, however, that American
College of Chest Physicians (ACCP) recommendations may have altered
practices of VTE prophylaxis in elective surgical patients, and rates of fatal
and non-fatal PE could be influenced by changing indications for VTE
prophylaxis. The authors’ study was designed to assess and compare rates of
VTE prophylaxis and PE from an 18-month consecutive period in 2003 to
2004 with an identical period of observation in 2007 to 2008. Their hope
was to assess the effect of the ACCP recommendations advocating an
increase in VTE prophylaxis.
The authors queried the University Health System Consortium data-
base comprising data from 123 academic teaching hospitals. They identified
patients undergoing colorectal resections, total hip replacement, total knee
replacement, and hysterectomies from two consecutive 18-month periods:
2003 to 2004 and 2007 to 2008. VTE rates ranged from 0.6% to 3.2%, and
PE rates ranged from 0.28% to 1.09%. There was an increased use of VTE
prophylaxis for all procedures between 2003 to 2004 and 2007 to 2008,
except for hysterectomy. Comparing the two periods, the authors found
VTE rates were not significantly affected among patients who received
pharmacologic prophylaxis and actually decreased in patients who did not
receive any pharmacologic prophylaxis, despite an absence of significant
change of severity of illness in the patient populations.
Comment: The author’s arguments are a step backward from routine
VTE prophylaxis to an approach where “the need for prophylaxis would be
assessed on an individual basis, based on retrospective data, expert consen-
sus, and clinical judgment.” What the authors may have actually found is that
in a practice where VTE prophylaxis is encouraged and withheld only for
specific reasons, the rate of VTE complications, specifically fatal PE, is low. It
does not follow that the same results can be obtained with the approach of
withholding VTE prophylaxis unless one judges it to be specifically required
in individual cases.
Anatomical and Technical factors Associated With Stroke or Death
During Carotid Angioplasty and Stenting Results from the Endarter-
ectomy Versus Angioplasty in Patients With Symptomatic Severe Ca-
rotid Stenosis (EVA-3S) Trial and Systematic Review
Naggara O, Touze E, Beyssen B, and the EVA-3S Investigators. Stroke
2011;42:380-8.
Conclusion: There are technical and anatomic factors, especially ex-
treme angulation of the carotid artery, that impact the risk of carotid artery
angioplasty and stenting.
Summary: It seems clear, at this point, that large randomized clinical
trials of 30-day stroke and death rates favor carotid endarterectomy (CEA)
over carotid artery stenting (CAS). However, once the perioperative period
has passed, CAS and CEA both appear effective in preventing midterm
stroke. The implication is decreasing periprocedural rates of CAS would
make the procedure more attractive because long-term stroke prevention
after CAS or CEA is more equivalent. The authors sought to assess relation-
ships between anatomic and technical factors and 30-day risk of stroke and
death after CAS. The authors included patients from the EVA-3S study
where carotid stenting was attempted. Two radiologist blinded to clinical
E
p
910ata independently assessed the aortic arch and the carotid arteries on
rocedural angiograms. The authors then also performed a systematic review
f studies of CAS that reported 30-day stroke or death risk in relation to
rterial anatomy and technique. End points were stroke or death and stroke
ccurring 30 days of CAS. In the EVA-3S trial, 262 patients fulfilled the
nclusion criteria, including 13 patients in whom stent insertion failed. The
0-day risk of stroke or death in these patients was 9.5% (n  25). The risk
f stroke or death was higher in patients with internal carotid artery-
ommon carotid artery angulation 60% (RR, 4.96; 2.29-10.74). Risk was
ower in patients treated with cerebral protection devices (RR, 0.38; 0.17-
.85).
The authors included 56 studies and 34,398 patients in a systemic
eview. Risk of stroke or death was higher in patients undergoing left carotid
AS (RR, 1.29; 1.05-1.58, P .02). Risk of stroke or death was also higher
n patients with increased internal carotid artery- common carotid artery
ngulation (RR, 3.41; 1.52- 7.63, P  .001) and when the target ICA
arotid stenosis was 10 mm in length (RR, 2.36; 1.28-3.38, P  .01).
here were nonsignificant trends toward increased risk with CAS in patients
ith type III aortic arch (RR, 1.82; 0.97-3.41, P  .06), in patients with
ighly calcified lesions (RR, 1.62; 0.99-2.64, P .05), and in patients with
n ostial location of the ICA stenosis (RR, 1.75; 0.99-3.11, P  .06). Also,
n the systematic review, cerebral protection devices were associated with a
ower risk of stroke or death (RR, 0.55; 0.41-0.73, P  .02). For the end
oint of stroke alone, lesion length10 mm, aortic arch calcification, ostial
ocation of the stenosis, and stenosis90% all were associated with increased
isk of CAS (all P  .05).
Comment: Patient selection is important in reducing the risk of any
rocedure. This report by the EVA-3S investigators is therefore an impor-
ant contribution to the CAS literature. Unfortunately, many of the ana-
omic risk factors for CAS identified will only be discovered during the
ourse of the angiogram accompanying the procedure. Perhaps the inci-
ence of 30-day stroke or death associated with CAS could be decreased if
perators were willing to back out of the procedure when an anatomic risk
actor for an adverse outcome is identified during the preliminary angio-
ram?
ngiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm
n Mice Through ERK Antagonism
abashi JP, Doyle JJ, Hokm TM, et al. Science 2011;332:361-4.
Conclusion: The selective angiotensin I receptor blocker losartan
revents aneurysm progression in a mouse model of Marfan disease with full
rotection requiring angiotensin II signaling.
Summary: The most common mutation in people with Marfan syn-
rome involves a cysteine substitution in the epidermal growth factor-like
omain of fibrillin-1. In fibrillin-1–deficient mice, the effects of the fibrillin-
mutation are attenuated by administration of polyclonal transforming
rowth factor (TGF)-–neutralizing antibodies. Protection can also be
btained by treating fribillin-1 mutated mice with losartan, an angiotensin II
ype I receptor blocker. The authors demonstrate in this work that loss of
ngiotensin II expression accelerates the aneurysm process in the mouse
odel of Marfan syndrome. They found full protection of aneurysm degen-
ration in the mouse model of Marfan syndrome required intact angiotensin
I receptor signaling. Enalapril, an angiotensin-converting enzyme inhibi-
or, limits angiotensin signaling for both angiotensin I and angiotensin II
eceptors and was less effective in decreasing the aneurysmal degeneration of
he aorta in fibrillin-1 mutated mice. The authors demonstrated that al-
hough enalapril and losartan both attenuated TGF- signaling in the aorta,
nly losartan inhibited TGF-–mediated activation of ERK, extracellular
ignal regulated kinase. The data indicate that the protective nature of
ngiotensin II signaling is necessary for angiotensin-converting enzyme
nhibitors to potentially decrease the aneurysmal degeneration of the aorta in
ice with fibrillin-1 deficiency resulting from a cysteine substitution. The
ata indicate losartan reduces ERK1/2 phosphorylation through a combi-
ation of inhibiting AT1 receptor-mediated ERK activation and shunting of
ngiotensin II signaling through the AT2 receptor.
Comment: Remarkable effects of losartan in decreasing aneurysmal
egeneration in a mouse model of Marfan syndrome have been previously
emonstrated. This study further extends previous work and indicates in the
resence of AT1 receptor blocking, ongoing AT2 receptor signaling is
equired for attenuation of ERK phosphorylation. This appears to be re-
uired for the favorable effect of losartan in attenuating aneurysmal degen-
ration in an animal model of human Marfan disease. Modification of the
RK 1/2 signaling cascade is potentially a therapeutic target for slowing or
reventing aneurysmal degeneration in patients with Marfan syndrome.
